Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_2
2
25%
Ph phase_3
4
50%
Ph phase_4
1
13%

Phase Distribution

0

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
4(57.1%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Other(1)

Detailed Status

Completed6
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (28.6%)
Phase 34 (57.1%)
Phase 41 (14.3%)

Trials by Status

unknown113%
completed675%
not_yet_recruiting113%

Recent Activity

0 active trials
Showing 5 of 8
not_yet_recruitingphase_4

A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia

NCT07256912
completedphase_3

Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts

NCT02750202
completedphase_3

Immunogenicity of HPV Vaccine in Immunosuppressed Children

NCT02263703
completedphase_3

ICI-VPH: Impact of HPV Immunisation Schedules Against HPV

NCT02009800
completedphase_2

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

NCT00604175
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07256912Phase 4

A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia

Not Yet Recruiting
NCT02750202Phase 3

Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts

Completed
NCT02263703Phase 3

Immunogenicity of HPV Vaccine in Immunosuppressed Children

Completed
NCT02009800Phase 3

ICI-VPH: Impact of HPV Immunisation Schedules Against HPV

Completed
NCT00604175Phase 2

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Completed
NCT01461096Phase 3

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

Completed
NCT04096911Phase 2

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Unknown
NCT01505049

Immune Memory After Papillomavirus Vaccination

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8